Stocktoria

REST EZ Inc. RTEZ

OTC · stock · Pharmaceutical Preparations · website · IPO 2023-02-02

REST EZ Inc. financials (annual)

Revenue
$105000 $519443 $0 $5000 $0 202120222023202420252026
Net income
-$23222 $171971 -$428706 -$19386 -$7900 -$14700 202120222023202420252026
Free cash flow
202120222023202420252026

Bars are annual figures from 2021 to 2026; red bars are negative (a loss or cash outflow).

MetricFY2026FY2025FY2024FY2023FY2022FY2021
Revenue—$0$5,000$0$519,443$105,000
Gross profit—$0$2,450$0$250,393$0
Operating income-$14,700-$7,900-$19,386-$418,408$223,642-$12,580
Interest expense—$0$0$10,298$9,984$10,642
Income tax—$0$0$0$41,687$0
Net income-$14,700-$7,900-$19,386-$428,706$171,971-$23,222
EPS (diluted)$0.00$0.00$0.00$-0.02$0.01$0.00
Operating cash flow$3,556-$44,705-$103,149-$13,312-$77,308$12,264
Cash & equivalents—$300$0$44$431$12,350
Inventory—$0$0$2,550$2,550$26,450
Total assets$3,856$300$13,500$2,594$407,981$118,950
Shareholders' equity-$14,400$300-$36,805-$170,564$247,844-$14,111

Growth · year-over-year

MetricFY2026FY2025FY2024FY2023FY2022FY2021
Revenue growth—-100.0%—-100.0%+394.7%—
Net income growth———-349.3%——
EPS growth———-300.0%——

Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.

Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.